GPT and palmoplantar pustulosis: As noted earlier in a cohort consisting of 28 PPP patients (10 males, 18 females, mean age 36.3 years) who were administered upadacitinib at a dosage of 15 mg daily, adverse effects such as acneiform rash in four patients (14.3%), transient transaminitis (ALT/AST < 2 × ULN) in two patients (7.1%) and a mild, self-resolving creatinine elevation in one patient (3.6%).